BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29218366)

  • 21. A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors.
    Pérez-Martínez A; Fernández L; Valentín J; Martínez-Romera I; Corral MD; Ramírez M; Abad L; Santamaría S; González-Vicent M; Sirvent S; Sevilla J; Vicario JL; de Prada I; Diaz MÁ
    Cytotherapy; 2015 Nov; 17(11):1594-603. PubMed ID: 26341478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease.
    Kordelas L; Steckel NK; Horn PA; Beelen DW; Rebmann V
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.
    Shah NN; Baird K; Delbrook CP; Fleisher TA; Kohler ME; Rampertaap S; Lemberg K; Hurley CK; Kleiner DE; Merchant MS; Pittaluga S; Sabatino M; Stroncek DF; Wayne AS; Zhang H; Fry TJ; Mackall CL
    Blood; 2015 Jan; 125(5):784-92. PubMed ID: 25452614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
    J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas.
    Porrata LF; Inwards DJ; Micallef IN; Johnston PB; Ansell SM; Hogan WJ; Markovic SN
    Clin Dev Immunol; 2010; 2010():914945. PubMed ID: 20414345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
    Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
    J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer cells in the treatment of high-risk acute leukaemia.
    Locatelli F; Moretta F; Brescia L; Merli P
    Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.
    Yu XX; Cao XH; Yan H; Luo XY; Zhao XS; Sun YQ; Wang Y; Xu LP; Zhang XH; Chang YJ; Huang XJ; Zhao XY
    Clin Immunol; 2019 Aug; 205():49-56. PubMed ID: 31112757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma.
    Nieto Y; Banerjee P; Kaur I; Kim KH; Fang D; Thall PF; Griffin L; Barnett M; Basar R; Hosing C; Ramdial J; Srour S; Daher M; Marin D; Jiang X; Chen K; Champlin R; Shpall EJ; Rezvani K
    Transplant Cell Ther; 2024 Feb; 30(2):203.e1-203.e9. PubMed ID: 38042257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.
    Williams RL; Cooley S; Bachanova V; Blazar BR; Weisdorf DJ; Miller JS; Verneris MR
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):618-622. PubMed ID: 29197679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.
    Cichocki F; Zhang B; Wu CY; Chiu E; Day A; O'Connor RS; Yackoubov D; Simantov R; McKenna DH; Cao Q; Defor TE; Janakiram M; Wangen R; Cayci Z; Snyder N; Kumar A; Grzywacz B; Hwang J; Geffen Y; Miller JS; Maakaron J; Bachanova V
    Sci Transl Med; 2023 Jul; 15(705):eade3341. PubMed ID: 37467318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma.
    Choi YB; Son MH; Cho HW; Ma Y; Lee JW; Kang ES; Yoo KH; Her JH; Lim O; Jung M; Hwang YK; Sung KW; Koo HH
    PLoS One; 2019; 14(12):e0225998. PubMed ID: 31834883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
    Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
    Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
    Shimoni A; Labopin M; Lorentino F; Van Lint MT; Koc Y; Gülbas Z; Tischer J; Bruno B; Blaise D; Pioltelli P; Afanasyev B; Ciceri F; Mohty M; Nagler A
    Leukemia; 2019 Jan; 33(1):230-239. PubMed ID: 29907809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decrease post-transplant relapse using donor-derived expanded NK-cells.
    Ciurea SO; Kongtim P; Soebbing D; Trikha P; Behbehani G; Rondon G; Olson A; Bashir Q; Gulbis AM; Indreshpal K; Rezvani K; Shpall EJ; Bassett R; Cao K; Martin AS; Devine S; Horowitz M; Pasquini M; Lee DA; Champlin RE
    Leukemia; 2022 Jan; 36(1):155-164. PubMed ID: 34312462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
    Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
    Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
    Khouri IF; Keating M; Körbling M; Przepiorka D; Anderlini P; O'Brien S; Giralt S; Ippoliti C; von Wolff B; Gajewski J; Donato M; Claxton D; Ueno N; Andersson B; Gee A; Champlin R
    J Clin Oncol; 1998 Aug; 16(8):2817-24. PubMed ID: 9704734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.